197 related articles for article (PubMed ID: 34607808)
1. Cytochrome P450 Binding and Bioactivation of Tumor-Targeted Duocarmycin Agents.
Bart AG; Morais G; Vangala VR; Loadman PM; Pors K; Scott EE
Drug Metab Dispos; 2022 Jan; 50(1):49-57. PubMed ID: 34607808
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 isoforms 1A1, 1B1 AND 2W1 as targets for therapeutic intervention in head and neck cancer.
Presa D; Khurram SA; Zubir AZA; Smarakan S; Cooper PA; Morais GR; Sadiq M; Sutherland M; Loadman PM; McCaul J; Shnyder SD; Patterson LH; Pors K
Sci Rep; 2021 Sep; 11(1):18930. PubMed ID: 34556703
[TBL] [Abstract][Full Text] [Related]
3. Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins.
Travica S; Pors K; Loadman PM; Shnyder SD; Johansson I; Alandas MN; Sheldrake HM; Mkrtchian S; Patterson LH; Ingelman-Sundberg M
Clin Cancer Res; 2013 Jun; 19(11):2952-61. PubMed ID: 23589180
[TBL] [Abstract][Full Text] [Related]
4. Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity.
Sheldrake HM; Travica S; Johansson I; Loadman PM; Sutherland M; Elsalem L; Illingworth N; Cresswell AJ; Reuillon T; Shnyder SD; Mkrtchian S; Searcey M; Ingelman-Sundberg M; Patterson LH; Pors K
J Med Chem; 2013 Aug; 56(15):6273-7. PubMed ID: 23844629
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder.
Sutherland M; Gill JH; Loadman PM; Laye JP; Sheldrake HM; Illingworth NA; Alandas MN; Cooper PA; Searcey M; Pors K; Shnyder SD; Patterson LH
Mol Cancer Ther; 2013 Jan; 12(1):27-37. PubMed ID: 23033491
[TBL] [Abstract][Full Text] [Related]
6. Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds.
Ortuzar N; Karu K; Presa D; Morais GR; Sheldrake HM; Shnyder SD; Barnieh FM; Loadman PM; Patterson LH; Pors K; Searcey M
Bioorg Med Chem; 2021 Jun; 40():116167. PubMed ID: 33932713
[TBL] [Abstract][Full Text] [Related]
7. Developmental regulation and induction of cytochrome P450 2W1, an enzyme expressed in colon tumors.
Choong E; Guo J; Persson A; Virding S; Johansson I; Mkrtchian S; Ingelman-Sundberg M
PLoS One; 2015; 10(4):e0122820. PubMed ID: 25844926
[TBL] [Abstract][Full Text] [Related]
8. CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610, NSC 721648) sensitivity in breast and colorectal cancer cells.
Tan BS; Tiong KH; Muruhadas A; Randhawa N; Choo HL; Bradshaw TD; Stevens MF; Leong CO
Mol Cancer Ther; 2011 Oct; 10(10):1982-92. PubMed ID: 21831963
[TBL] [Abstract][Full Text] [Related]
9. Bioactivation of fluorinated 2-aryl-benzothiazole antitumor molecules by human cytochrome P450s 1A1 and 2W1 and deactivation by cytochrome P450 2S1.
Wang K; Guengerich FP
Chem Res Toxicol; 2012 Aug; 25(8):1740-51. PubMed ID: 22734839
[TBL] [Abstract][Full Text] [Related]
10. CYP2W1 polymorphism: functional aspects and relation to risk for colorectal cancer.
Stenstedt K; Travica S; Guo J; Barragan I; Pors K; Patterson L; Edler D; Mkrtchian S; Johansson I; Ingelman-Sundberg M
Pharmacogenomics; 2013 Oct; 14(13):1615-22. PubMed ID: 24088132
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 2W1 (CYP2W1) - ready for use as the biomarker and drug target for cancer?
Pan Y; Ong EC
Xenobiotica; 2017 Oct; 47(10):923-932. PubMed ID: 27690753
[TBL] [Abstract][Full Text] [Related]
12. Colorectal cancer-specific cytochrome P450 2W1: intracellular localization, glycosylation, and catalytic activity.
Gomez A; Nekvindova J; Travica S; Lee MY; Johansson I; Edler D; Mkrtchian S; Ingelman-Sundberg M
Mol Pharmacol; 2010 Dec; 78(6):1004-11. PubMed ID: 20805301
[TBL] [Abstract][Full Text] [Related]
13. Human Cytochrome P450 2W1 Is Not Expressed in Adrenal Cortex and Is Only Rarely Expressed in Adrenocortical Carcinomas.
Nolé P; Duijndam B; Stenman A; Juhlin CC; Kozyra M; Larsson C; Ingelman-Sundberg M; Johansson I
PLoS One; 2016; 11(9):e0162379. PubMed ID: 27598485
[TBL] [Abstract][Full Text] [Related]
14. Molecular modeling of human cytochrome P450 2W1 and its interactions with substrates.
Li W; Tang Y; Hoshino T; Neya S
J Mol Graph Model; 2009 Sep; 28(2):170-6. PubMed ID: 19596602
[TBL] [Abstract][Full Text] [Related]
15. The CYP2W1 enzyme: regulation, properties and activation of prodrugs.
Guo J; Johansson I; Mkrtchian S; Ingelman-Sundberg M
Drug Metab Rev; 2016 Aug; 48(3):369-78. PubMed ID: 27257736
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of cytochrome P450 enzymes in normal and tumor tissues from childhood rhabdomyosarcoma.
Molina-Ortiz D; Camacho-Carranza R; González-Zamora JF; Shalkow-Kalincovstein J; Cárdenas-Cardós R; Ností-Palacios R; Vences-Mejía A
PLoS One; 2014; 9(4):e93261. PubMed ID: 24699256
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 2W1 (CYP2W1) in Colorectal Cancers.
Chung FF; Mai CW; Ng PY; Leong CO
Curr Cancer Drug Targets; 2016; 16(1):71-8. PubMed ID: 26563883
[TBL] [Abstract][Full Text] [Related]
18. Branched alkyl of phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates as unique cytochrome P450 1A1-activated antimitotic prodrugs: Biological evaluation and mechanism of bioactivation.
Bouzriba C; Chavez Alvarez AC; Gagné-Boulet M; Ouellette V; Lacroix J; Côté MF; C-Gaudreault R; Fortin S
Eur J Med Chem; 2022 Feb; 229():114003. PubMed ID: 34839998
[TBL] [Abstract][Full Text] [Related]
19. Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity.
Pors K; Loadman PM; Shnyder SD; Sutherland M; Sheldrake HM; Guino M; Kiakos K; Hartley JA; Searcey M; Patterson LH
Chem Commun (Camb); 2011 Nov; 47(44):12062-4. PubMed ID: 22002321
[TBL] [Abstract][Full Text] [Related]
20. 4-(3-Alkyl-2-oxoimidazolidin-1-yl)-N-phenylbenzenesulfonamide salts: Novel hydrosoluble prodrugs of antimitotics selectively bioactivated by the cytochrome P450 1A1 in breast cancer cells.
Ouellette V; Chavez Alvarez AC; Bouzriba C; Hamel-Côté G; Fortin S
Bioorg Chem; 2023 Nov; 140():106820. PubMed ID: 37672952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
